TP 0586532
Alternative Names: TP-0586532Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Taisho Pharmaceutical
- Class Antibacterials
- Mechanism of Action LpxC inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Gram-negative-infections in Japan
- 22 Jun 2020 Preclinical trials in Gram-negative infections in Japan (unspecified route)
- 22 Jun 2020 Antimicrobial data from preclinical studies in bacterial presented at the ASM Microbe 2020 (ASMM-2020)